Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy ...Middle East

SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART® Hytrulo prefilled syringe for self-injection (efgartigimod alfa and hyaluronidase-qvfc) for...

Hence then, the article about halozyme announces fda approval of argenx s vyvgart hytrulo prefilled syringe co formulated with enhanze for self injection for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy was published today ( Friday 11/04/2025 - 01:19 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy )

Also on site :

• The Good Ship Murder Christmas special cast: Meet the characters
• No. 20 Virginia notches first 11-win season by beating 25th-ranked Missouri in the Gator Bowl
• SK Telecom Unveils A.X K1, Korea's First 500B-Scale Hyperscale AI Model